The Oncology Institute, Inc. Warrant

The Oncology Institute, Inc. (NASDAQ: TOI) announced it will release its first quarter 2026 financial results on May 7, 2026, followed by a conference call at 5:30 p.m. ET. The company also recently achieved $1.8 million in Medicare savings in the CMS Enhancing Oncology Model Performance Period 3, marking significant period-over-period improvement.

M33 Growth, a Boston-based venture firm, announced a partnership with U.S. Neurology Associates (USNA), a physician services organization focused on community-based neurology care. Nitin Jain will serve as CEO and Brad Hively as Chairman. USNA aims to provide comprehensive, integrated neurological care including in-office infusions, diagnostics, ...

The Oncology Institute promoted Rakesh Panda to Chief Information Officer and Nolan Mariano to Chief People Officer. Panda brings 25+ years of IT and digital transformation experience from roles at Cisco and Infosys, while Mariano brings 18 years of People Operations experience. The promotions support TOI's growth in value-based cancer care and t...

The Oncology Institute (TOI) has seen a massive stock rally of over 950% in 2025, driven by its value-based cancer care approach, AI-driven operational efficiencies, and potential for growth across multiple states.

The Oncology Institute reported Q2 2025 revenue of $119.8 million, a 21.5% year-over-year increase, driven by strong pharmacy segment performance. Despite revenue growth, the company continues to face challenges with net losses and cash burn.